Indoramin in severe congestive heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Severe congestive heart failure (CHF) presents significant hemodynamic challenges.
• Alpha 1-adrenoceptor antagonists are explored for their vasodilating properties in cardiovascular conditions.

Purpose of the Study:

• To evaluate the acute and chronic effects of indoramin in patients with severe congestive heart failure (New York Heart Association class III or IV).

Main Methods:

• Acute phase: Intravenous administration of indoramin (0.2-0.4 mg/kg) to 12 severe CHF patients.
• Hemodynamic parameters including systemic peripheral resistance, heart pressures, cardiac output, and ejection fraction were measured.
• Chronic phase: Eight patients were monitored for changes in blood pressure and heart rate.

Main Results:

• Acute indoramin administration significantly improved hemodynamic parameters, including decreased systemic vascular resistance and pulmonary artery pressure, and increased cardiac index and left ventricular ejection fraction.
• Significant reductions observed in mean arterial pressure, mean pulmonary artery pressure, total systemic peripheral resistance, and left ventricular end-diastolic pressure.
• Cardiac index increased from 2.1 to 3.3 L/min/m², and left ventricular ejection fraction rose from 29.0% to 42.5% (p < 0.001).
• No significant changes in heart rate or arteriovenous oxygen difference were noted during the acute phase.

Conclusions:

• Indoramin demonstrates potent acute vasodilating effects, significantly improving cardiac function in severe congestive heart failure patients.
• The drug effectively reduces preload and afterload, leading to enhanced cardiac output and ejection fraction.
• Further research may be warranted to explore long-term efficacy and safety profiles, as chronic administration showed no significant hemodynamic alterations.